Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics

Kidney cancer is not a single disease; it is made up of a number of different types of cancer, including clear cell, type 1 papillary, type 2 papillary, chromophobe, TFE3, TFEB, and oncocytoma. Sporadic, nonfamilial kidney cancer includes clear cell kidney cancer (75%), type 1 papillary kidney cancer (10%), papillary type 2 kidney cancer (including collecting duct and medullary RCC) (5%), the microphalmia-associated transcription (MiT) family translocation kidney cancers (TFE3, TFEB, and MITF), chromophobe kidney cancer (5%), and oncocytoma (5%). Each has a distinct histology, a different clinical course, responds differently to therapy, and is caused by mutation in a different gene. Genomic studies identifying the genes for kidney cancer, including the VHL, MET, FLCN, fumarate hydratase, succinate dehydrogenase, TSC1, TSC2, and TFE3 genes, have significantly altered the ways in which patients with kidney cancer are managed. While seven FDA-approved agents that target the VHL pathway have been approved for the treatment of patients with advanced kidney cancer, further genomic studies, such as whole genome sequencing, gene expression patterns, and gene copy number, will be required to gain a complete understanding of the genetic basis of kidney cancer and of the kidney cancer gene pathways and, most importantly, to provide the foundation for the development of effective forms of therapy for patients with this disease.

[1]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[2]  W Marston Linehan,et al.  A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jeffrey E. Barrick,et al.  Repeatability and Contingency in the Evolution of a Key Innovation in Phage Lambda , 2012, Science.

[4]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[5]  W. Marston Linehan,et al.  Reductive carboxylation supports growth in tumor cells with defective mitochondria , 2011, Nature.

[6]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[7]  S. Puig,et al.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.

[8]  W. Marston Linehan,et al.  Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors , 2011, PLoS genetics.

[9]  Vladimir Valera Romero,et al.  The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. , 2011, Cancer cell.

[10]  A. Gill,et al.  Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. , 2011, The New England journal of medicine.

[11]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[12]  W. Linehan,et al.  Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit. , 2010, The Journal of urology.

[13]  Paolo Vineis,et al.  Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3 , 2011, Nature Genetics.

[14]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[15]  M. Ladanyi,et al.  Xp11 Translocation Renal Cell Carcinoma (RCC): Extended Immunohistochemical Profile Emphasizing Novel RCC Markers , 2010, The American journal of surgical pathology.

[16]  W. Linehan,et al.  The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.

[17]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Guo-Ping Zhao,et al.  Acetylation of Metabolic Enzymes Coordinates Carbon Source Utilization and Metabolic Flux , 2010, Science.

[19]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[20]  W. Linehan,et al.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. , 2010, Cancer genetics and cytogenetics.

[21]  W. Gregory,et al.  Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[22]  W. Linehan,et al.  Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2 , 2009, Proceedings of the National Academy of Sciences.

[23]  Arianna Di Napoli,et al.  Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. , 2009, Cancer research.

[24]  W. Kaelin The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.

[25]  C. Ricketts,et al.  Germline SDHB mutations and familial renal cell carcinoma. , 2008, Journal of the National Cancer Institute.

[26]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[27]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[28]  N. Rioux-Leclercq,et al.  Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma , 2008, International journal of cancer.

[29]  Seung-Beom Hong,et al.  Identification and characterization of a novel folliculin-interacting protein FNIP2. , 2008, Gene.

[30]  S. Steinberg,et al.  BHD mutations, clinical and molecular genetic investigations of Birt–Hogg–Dubé syndrome: a new series of 50 families and a review of published reports , 2008, Journal of Medical Genetics.

[31]  P. Choyke,et al.  Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. , 2008, Journal of the National Cancer Institute.

[32]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[33]  M. Merino,et al.  The Morphologic Spectrum of Kidney Tumors in Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome , 2007, The American journal of surgical pathology.

[34]  P. Choyke,et al.  Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. , 2007, The Journal of urology.

[35]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[36]  S. Richard,et al.  Mutations in BHD and TP53 genes, but not in HNF1β gene, in a large series of sporadic chromophobe renal cell carcinoma , 2007, British Journal of Cancer.

[37]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[38]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[39]  S. Richard,et al.  Mutations in BHD and TP53 genes, but not in HNF1β gene, in a large series of sporadic chromophobe renal cell carcinoma , 2006, British Journal of Cancer.

[40]  J. Hartley,et al.  Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling , 2006, Proceedings of the National Academy of Sciences.

[41]  Kentaro Takahashi,et al.  Von Hippel-Lindau Disease , 2024 .

[42]  Robert Tibshirani,et al.  Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma , 2005, PLoS medicine.

[43]  W. Linehan,et al.  High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. , 2005, Journal of the National Cancer Institute.

[44]  P. Choyke,et al.  Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer , 2005, Journal of Medical Genetics.

[45]  Yuen-Li Chung,et al.  HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. , 2005, Cancer cell.

[46]  Peter Choyke,et al.  Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. , 2005, The Journal of urology.

[47]  W. Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2004, Clinical Cancer Research.

[48]  J. Yang Bevacizumab for Patients with Metastatic Renal Cancer , 2004, Clinical Cancer Research.

[49]  W Marston Linehan,et al.  Focus on kidney cancer. , 2004, Cancer cell.

[50]  C. Eng,et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.

[51]  P. Albert,et al.  Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location , 2004, Human mutation.

[52]  L. Aaltonen,et al.  Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. , 2004, American journal of human genetics.

[53]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[54]  P. Choyke,et al.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. , 2003, American journal of human genetics.

[55]  Joanna H Shih,et al.  Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Ladanyi,et al.  Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  N. Hoogerbrugge,et al.  Chromosome 3 translocations and the risk to develop renal cell cancer: a Dutch intergroup study. , 2003, Genetic counseling.

[58]  Ximing J. Yang,et al.  Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics. , 2003, Advances in cancer research.

[59]  Ximing J. Yang,et al.  Molecular subclassification of kidney tumors and the discovery of new diagnostic markers , 2003, Oncogene.

[60]  W. Linehan,et al.  Renal Tumors in the Birt-Hogg-Dubé Syndrome , 2002, The American journal of surgical pathology.

[61]  M. Copin,et al.  Morphologic Subtyping of Papillary Renal Cell Carcinoma: Correlation with Prognosis and Differential Expression of MUC1 between the Two Subtypes , 2002, Modern Pathology.

[62]  J. Gulcher,et al.  A population‐based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas , 2002, International journal of cancer.

[63]  Maria Merino,et al.  Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.

[64]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[65]  P. Choyke,et al.  Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[66]  K. Huebner,et al.  Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation , 2001, Journal of Human Genetics.

[67]  P. Argani,et al.  A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. , 2001, The American journal of pathology.

[68]  Parenchymal sparing surgery in a patient with multiple bilateral papillary renal cancer. , 2001, The Journal of urology.

[69]  M. Ligtenberg,et al.  Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15) , 2001, Genes, chromosomes & cancer.

[70]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[71]  P L Choyke,et al.  Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. , 2001, The Journal of urology.

[72]  L. Aaltonen,et al.  Inherited susceptibility to uterine leiomyomas and renal cell cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[73]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[74]  D. Ornstein,et al.  Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. , 2000, The Journal of urology.

[75]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[76]  S. Elledge,et al.  Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. , 1999, Science.

[77]  W. Linehan,et al.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.

[78]  W. Marston Linehan,et al.  Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.

[79]  W. Linehan,et al.  Improved detection of germline mutations in the von Hippel‐Lindau disease tumor suppressor gene , 1998, Human mutation.

[80]  Damian Smedley,et al.  Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma , 1997, Oncogene.

[81]  B. Delahunt,et al.  Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[82]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[83]  W. Linehan,et al.  Re: Hereditary Papillary Renal Cell Carcinoma; Re Hereditary Papillary Renal Cell Carcinoma Clinical Studies in 10 Families , 1996 .

[84]  J. Wehland,et al.  IrpA , is highly homologous to monocytogenesPrfA-regulated gene in Listeria Identification and characterization of a novel , 1996 .

[85]  W. Linehan,et al.  Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. , 1995, The Journal of urology.

[86]  D. Duan,et al.  Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.

[87]  A. Kibel,et al.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.

[88]  L. Schmidt,et al.  Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. , 1995, The cancer journal from Scientific American.

[89]  P. Choyke,et al.  Original Articles: Kidney Cancer , 1995 .

[90]  A. Knudson VHL gene mutation and clear-cell renal carcinomas. , 1995, The cancer journal from Scientific American.

[91]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[92]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[93]  P. Choyke,et al.  Hereditary papillary renal cell carcinoma. , 1994, The Journal of urology.

[94]  D. Kwiatkowski,et al.  Tuberous sclerosis. , 1994, Archives of dermatology.

[95]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[96]  G. H. Weiss,et al.  Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. , 1991, Cancer research.

[97]  P. Choyke,et al.  Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. , 1990, Genomics.

[98]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[99]  H. Brauch,et al.  Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma , 1988, Nature.

[100]  S. Jacobs,et al.  Hereditary renal-cell carcinoma associated with a chromosomal translocation. , 1979, The New England journal of medicine.

[101]  E. Mazeman [CANCER OF THE KIDNEY]. , 1963, Lille chirurgical.

[102]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[103]  M. GreyJde [Cancer of the kidney]. , 1950, L' Hopital.